Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study
An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. The findings, published in Nature Medicine, will help researchers design a larger phase 3 clinical trial.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
